Does IgA antibody against β2 glycoprotein I increase cardiovascular risk in hemodialysis patients?
King's Thrombosis Centre, Department of Haematological Medicine, King's College Hospital, London, UK. Kidney International
(Impact Factor: 8.56).
06/2012; 81(12):1164-6. DOI: 10.1038/ki.2012.35
Cardiovascular disease is the most common cause of mortality in patients with chronic kidney disease on hemodialysis. In addition to a high prevalence of traditional cardiovascular risk factors, other specific factors, including uremia and chronic inflammation, seem to contribute to the excess cardiovascular mortality. The findings of Serrano et al. point to a link between IgA antibodies against β2 glycoprotein I and cardiovascular events in renal dialysis patients.
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.